上海医药(02607.HK)：硫酸羟氯喹片获得菲律宾药品注册证书

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, which are now approved for market launch [1] Group 1 - The approved drug, Hydroxychloroquine Sulfate Tablets, is primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin diseases triggered or exacerbated by sunlight [1]